3Schiller JH, Harrington D. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [ J ] . N Engl J Med, 2002, 346: 92-98.
4Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [ J ] . Semi Oncol, 1999, 26 ( Supp 1) : 3-10.
5Nicholas J. Vogelzang, James J. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [ J ] .J Clin Oncol, 2003,21:2636-2644.
6Rusthoven J, Eisenhaucr E, Butts C, et al. Muhitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small cell lung cancer: a phase Ⅱ study [ J ] . J Clin Oncol, 1999, 17: 1194-1199.
7Clarke S J, Abratt R, Goedhals L, et al. Phase Ⅱ trial of pemetrexed disodium in chemotherapy-naive patients with advanced non-small cell lung cancer [ J ] . Ann Oncol, 2002, 13: 737-741.
8Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase [ J ] . Cancer,2006, 107: 1589-1596.
9Hanna N, Frances A. Shepherd, Frank V. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy [ J ] .J Clin Oncol, 2004, 22: 1589-1597.
10Scaglioti G, Parikh P, yon Pawel J, et al. Phase m study comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemotherapy:naive patients with advanced-stage non-small cell lung cancer [ J ] . J Clin Oncol, 2008, 26:3543-3551.
3Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J]. J Clin Oncol, 2004, 22(8): 1589-1597.
4Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, amultitargeted antifolate, and cisplatin as first-line therapy in patientswith advanced non- small cell lung carcinoma [J]. Cancer (Phila), 2001,92(3): 595-600.
5Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC [J]. J Clin Oncot, 2008, 26(21): 3543-3551.
6Tony S, Mork, Yi Long Wu, et al. Gctitinib of carboplatin paclltaxed in pulmonary adcnocarcinoma [J]. N Engl J Med, 2009, 361: 947.
7Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced nonrsmall-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 1999, 17(4): 1994.
8Shepherd FA, Dancry J, Arnold A, et al. Phase II study of pemetrexed disodium, a mulfitargeted antifolate, and eisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Groula [J] Cancer, 2001, 92(3): 595.
